Tumor Markers, Biological

• 

  Subject Areas on Research

  • 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. 
  • A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. 
  • A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. 
  • A new tumor marker for Wilm's tumor called hyaluronic acid-stimulating activity (HASA) 
  • A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer. 
  • A pathological fracture and a solitary mass in the right clavicle: an unusual first presentation of HCC and the role of immunohistochemistry. 
  • A phase I surrogate endpoint study of SU6668 in patients with solid tumors. 
  • A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. 
  • A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma. 
  • A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. 
  • Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. 
  • Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. 
  • Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. 
  • Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. 
  • Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. 
  • Akt expression may predict favorable prognosis in cholangiocarcinoma. 
  • Alveolar soft-part sarcoma: a review and update. 
  • An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma. 
  • Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Anaplastic lymphoma kinase (ALK1) immunohistochemistry in diagnostic dermatopathology; an update. 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. 
  • Assessment of pancreatic duct strictures. 
  • BP1, a new homeobox gene, is frequently expressed in acute leukemias. 
  • Biomarkers in castration-resistant prostate cancer. 
  • Biomarkers in the ovary. 
  • Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. 
  • Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. 
  • Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. 
  • Breast cancer screening-individualized risk assessment and application of new research technology: non-protein bound estradiol and chromosome analysis. 
  • CD10 expression in trichoepithelioma and basal cell carcinoma. 
  • CD34 and α smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. 
  • CD34 expression in desmoplastic melanoma. 
  • CD38 variation as a prognostic factor in chronic lymphocytic leukemia. 
  • COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. 
  • Cell adhesion protein expression in melanocytic matricoma. 
  • Characterization of 67 kD laminin receptor, a protein whose gene is overexpressed on treatment of cells with anti-benzo[a]pyrene-7,8-diol-9,10-epoxide. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Circulating glycoconjugates in CSF of meningioma patients. 
  • Clear cell hidradenoma: a mimic of metastatic clear cell tumors. 
  • Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. 
  • Clinical validation of a customized multiple signature microarray for breast cancer. 
  • Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. 
  • Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. 
  • Combined genome-wide scan for prostate cancer susceptibility genes. 
  • Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. 
  • Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. 
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer. 
  • Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient. 
  • Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. 
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. 
  • Correspondence re: Geradts J, Wilentz RE, Roberts H. Immunohistochemical detection of the alternate ink4a-encoded tumor suppressor protein p14(arf) in archival human cancers and cell lines using commercial antibodies: correlation with p16(ink4a) expression. Mod pathol 2001;14:1162-68. 
  • Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. 
  • Current advances in the diagnosis and treatment of pancreatic endocrine tumors. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). 
  • Definition of a functional single nucleotide polymorphism in the cell migration inhibitory gene MIIP that affects the risk of breast cancer. 
  • Delta-like 1 homolog (dlk1): a marker for rhabdomyosarcomas implicated in skeletal muscle regeneration. 
  • Detection of stool DNA mutations before and after treatment of colorectal neoplasia. 
  • Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. 
  • Diagnostic strategies for unknown primary cancer. 
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. 
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer. 
  • Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. 
  • Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. 
  • Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. 
  • Elevation of multiple serum markers in patients with stage I ovarian cancer. 
  • Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. 
  • Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. 
  • Epithelioid and epithelial neoplasms of bone. 
  • Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. 
  • Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. 
  • Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. 
  • Fibrosarcoma-like lipomatous neoplasm: a reappraisal of so-called spindle cell liposarcoma defining a unique lipomatous tumor unrelated to other liposarcomas. 
  • Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. 
  • Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. 
  • Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. 
  • Genetic variants in predicting aggressive prostate cancer: "ready for prime time?". 
  • Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. 
  • Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. 
  • Giant cell tumor of rib masquerading as thymoma: a diagnostic pitfall in needle core biopsy of the mediastinum. 
  • Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. 
  • Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. 
  • Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 
  • Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. 
  • Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). 
  • High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. 
  • Hyaluronidase levels in urine from Wilms' tumor patients. 
  • Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. 
  • Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. 
  • Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. 
  • Image-based determination of 'physiomarkers' for personalized cancer therapy. 
  • Immunobiology of malignant astrocytomas. 
  • Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 
  • Immunohistochemistry in the diagnosis of cutaneous neoplasms. 
  • Immunotargeted nanoshells for integrated cancer imaging and therapy. 
  • Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy. 
  • Improvement for identification of heterophile antibody interference and AFP hook effect in immunoassays with multiplex suspension bead array system. 
  • Improving evidence developed from population-level experience with targeted agents. 
  • Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. 
  • Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. 
  • Integration of biomarkers and imaging. 
  • Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? 
  • Investigation momentum: the relentless pursuit to resolve uncertainty. 
  • Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis. 
  • Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
  • Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
  • Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. 
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. 
  • Lymphoma of the female genital tract: current status. 
  • MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. 
  • Making an imperfect marker better. 
  • Meningioma of the fourth ventricle. 
  • Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. 
  • Metastatic Merkel cell carcinoma (MCC) of pancreas and breast: a unique case. 
  • Metastatic cutaneous carcinoid tumor mimicking an adnexal poroid neoplasm. 
  • Micropapillary thyroid carcinoma and concomitant ectopic thyroid tissue in the adrenal gland: metastasis or metaplasia? 
  • Molecular biologic staging of lung cancer. 
  • Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Molecular signatures of thyroid follicular neoplasia. 
  • Monoclonal antibody against human colonic sulfomucin: immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. 
  • Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification: are marginal zone lymphomas in the orbit mucosa-associated lymphoid tissue-type lymphomas? 
  • Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • NCCN task force report: molecular markers in leukemias and lymphomas. 
  • Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. 
  • Non-small cell lung cancer. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. 
  • OVX1 as a marker for early stage endometrial carcinoma. 
  • OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. 
  • Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • Overexpression of synuclein-gamma in pancreatic adenocarcinoma. 
  • P-glycoprotein levels predict poor outcome in patients with osteosarcoma. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • Paget disease of the vulva: a histologic study of 56 cases correlating pathologic features and disease course. 
  • Pancreatoblastoma in a teenage patient. 
  • Panel of serum biomarkers for the diagnosis of lung cancer. 
  • Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. 
  • Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. 
  • Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. 
  • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 
  • Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. 
  • Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. 
  • Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. 
  • Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. 
  • Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. 
  • Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. 
  • Primary intraocular T-cell-rich large B-cell lymphoma. 
  • Primary lung cancer vs metastatic breast cancer: a probabilistic approach. 
  • Primary mucinous carcinoma of the eyelid: a clinicopathologic and immunohistochemical study of 4 cases and an update on recurrence rates. 
  • Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. 
  • Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. 
  • Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. 
  • Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. 
  • Prostate Cancer and Prostatic Diseases. Editor's comments. 
  • Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. 
  • Pulmonary and mediastinal glomus tumors--report of five cases including a pulmonary glomangiosarcoma: a clinicopathologic study with literature review. 
  • RE: net risk reclassification P Values: valid or misleading? 
  • Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. 
  • Radiotherapy for locally recurrent prostate cancer. 
  • Rationale for percutaneous biopsy and histologic characterisation of renal tumours. 
  • Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. 
  • Recent developments in predicting thyroid malignancy. 
  • Refocusing the war on cancer: the critical role of personalized treatment. 
  • Relative quantification based on logistic models for individual polymerase chain reactions. 
  • Reply: To PMID 25432832. 
  • Resection of adrenocortical carcinoma liver metastasis: is it justified? 
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. 
  • S100 A6 immunohistochemical staining for spindle cell and desmoplastic melanomas. 
  • Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. 
  • Screening for the breast cancer gene (BRCA1) using a biochip system and molecular beacon probes immobilized on solid surfaces. 
  • Secretory meningiomas of the orbit. 
  • Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. 
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. 
  • Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. 
  • Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. 
  • Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. 
  • Statistical considerations and modeling of clinical utility of tumor markers. 
  • Status of high-dose chemotherapy for breast cancer: a review. 
  • Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Surrogate markers in antiangiogenesis clinical trials. 
  • Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. 
  • The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. 
  • The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. 
  • The application of monoclonal antibodies in the cytologic evaluation of tumors. 
  • The common acute lymphoblastic leukemia antigen (neutral endopeptidase-3.4.24.11) gene is located on human chromosome 3. 
  • The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. 
  • The current clinical value of the DCIS Score. 
  • The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? 
  • The influence of statin medications on prostate-specific antigen levels. 
  • The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2. 
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. 
  • The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. 
  • Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. 
  • Tissue self-affinity and polarized light scattering in the born approximation: a new model for precancer detection. 
  • Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. 
  • Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor marker expression is predictive of survival in patients with esophageal cancer. 
  • Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. 
  • Two serologic markers to monitor the engraftment, growth, and treatment response of human leukemias in severe combined immunodeficient mice. 
  • Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. 
  • Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis. 
  • Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. 
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. 
  • Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. 
  • Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. 
  • Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. 
  • Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. 
  • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 
  • c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. 
  • p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Professor of Medical Oncology, Medicine, Medical Oncology
  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology
  • Chitneni, Satish K., Assistant Professor of Radiology, Radiology
  • Clyde, Merlise, Professor of Statistical Science, Statistical Science
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Professor of Otolaryngology, Head & Neck Surgery, Surgery, Head and Neck Surgery and Communication Sciences
  • Gottlin, Elizabeth B., Assistant Professor in Radiology, Radiology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Hartemink, Alexander J., Professor in the Department of Computer Science, Biology
  • Hirschey, Matthew, Associate Professor in Medicine, Pharmacology & Cancer Biology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Pharmacology & Cancer Biology
  • Lopez, Giselle Yvette, Assistant Professor in Pathology, Pathology
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Woodward, Julie Ann, Professor of Ophthalmology, Dermatology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology